All-Ohio Medical School Opioid Use Disorder Collaborative Curriculum

This 8-hour training is required by SAMHSA and the DEA in order for practitioners to prescribe buprenorphine products for the treatment of Opioid Use Disorders. After completion of this training, and when the practitioner has an independent medical license and DEA number, an online application is completed and within 30 to 45 days, practitioner may begin using buprenorphine for OUD treatment using an X-DEA number.

Instructional Strategy: Lecture/Discussion, Online modules, 8 hours

Learning Objectives

1. Review addiction identification and evidence-based treatments.  
2. Discuss the pharmacology of opioids as it relates to the treatment of opioid use disorder (OUD) patients.  
3. Describe the fundamentals of office-based opioid treatment including the treatment of the co-morbid patient.  
4. Explain the process of buprenorphine induction as well as stabilization and maintenance.  
5. Discuss other approved antagonist and agonist medications to treat OUD.  
6. Discuss basic office protocols including medical record documentation and confidentially.  
7. Utilize evidence-based resources to ensure providers have the confidence to prescribe buprenorphine for patients with OUD.   
8. Apply for a MAT Waiver Training Certificate to begin treating patients with OUD. 

Author: Christina Delos Reyes, MD

School: Case Western Reserve University, University Hospitals

• PCSS website provides a HUGE amount (overwhelming actually!) of resources: https://pcssnow.org/ ​  
• ​SAMHSA TIP 63 https://www.store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document-Including-Executive-Summary-and-Parts-1-5-/SMA18-5063FULLDOC